FDA 세계 최초 승인 줄기세포 임상에도 기술 지원 확인
메디포스트.산성피앤씨,에프씨비투웰브.차바이오앤,이노셀,알앤엘바이오
Neuralstem Receives Russian Patent for Stem Cell Transplantation to Treat Neurodegenerative Conditions
ROCKVILLE, Md., July 21, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has received a patent covering the transplantation of human neural cells for the treatment of neurodegenerative conditions from the Russian Federation. The claims include methods of culturing the cells as well as treating amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), spinal cord injuries, traumatic brain injury, multiple sclerosis, cerebral palsy, epilepsy, Huntington's disease and other conditions through cell transplantation. Neuralstem is currently sponsoring the world's first FDA-approved trial to treat ALS with its spinal cord stem cells and has applied to the FDA to initiate a stem cell trial in chronic spinal cord injury.
첫댓글 감사합니다..